Sector News

Pharma’s top 10 M&A deals of 2014

February 18, 2015
Life sciences
2014 was quite the banner year for pharma M&A. According to EY’s annual firepower report, deals topped $200 billion–well over twice the average volume from over the past decade.
 
And those were just the deals that ultimately went through. Some of the most talked-about M&A storylines last year included Pfizer’s failed $118 billion-plus bid for rival AstraZeneca and AbbVie’s canceled $55 billion merger with Ireland’s Shire–moves that could have taken the buyout record into an entirely different stratosphere.
 
So why all the wheeling and dealing? A few reasons. When it comes to Big Pharma, companies have been jumping on the slim-down bandwagon like there’s no tomorrow to zero in on their core strengths. That’s what led Merck to unload its consumer health unit–snapped up by Bayer–and it prompted GlaxoSmithKline and Novartis’ multibillion-dollar asset swap as well as the latter’s animal health unit sale to Eli Lilly.
 
Then there was the tax inversion craze, which saw pharma companies snapping up their tax-advantaged counterparts overseas to lower their rates. The U.S. Treasury eventually rolled out new, stricter tax rules to discourage the practice, but not before Mylan got its hands on a Netherlands-based piece of Abbott’s generics business, for one.
 
Activist investing played a role, too–and Actavis reaped the rewards, locking down the top two deals of last year. Notorious proxy brawler Carl Icahn declared a victory back in February when the long-embattled Forest Labs finally agreed to sell itself to the Dublin drugmaker. And 9 months later, CEO Brent Saunders’ company expanded once again with its white knight swoop-in for Allergan, a company looking for refuge after a months-long pursuit by Valeant and its activist investor partner Bill Ackman.
 
While 2015 may not measure up to the historic 2014 when all is said and done, it should see its fair share of deal action, especially since none of these trends seem to be going away. Even the Treasury rules won’t stop the most determined tax inverters–just ask Pfizer CEO Ian Read, who has said more than once that his company is scouting for one. And the ball is already rolling, with Shire’s agreement for NPS Pharmaceuticals and Pfizer’s pact to buy Hospira helping kick off the year.
 
So stay tuned to see what 2015 has in store, but in the meantime, take a trip down memory lane with last year’s top 10 pickups. And as always, feel free to get in touch with comments, questions and the like.
 
By Carly Helfand and Eric Palmer
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).